Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 22, 2015, 41 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $39.80 to $4,886,077.92.

Highlighted Stocks Traded by Insiders:

PetMed Express (PETS) - FREE Research Report

Akdag Menderes, who is CEO & President at PetMed Express, sold 60,000 shares at $15.63 on Jan. 22, 2015. Following this transaction, the CEO & President owned 558,000 shares meaning that the stake was reduced by 9.71% with the 60,000-share transaction.

The shares most recently traded at $15.94, up $0.31, or 1.94% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 2,667
  • 12-Week # shares sold: 2,667
  • 24-Week # shares sold: 5,167

The average volume for PetMed Express has been 164,500 shares per day over the past 30 days. PetMed Express has a market cap of $328.3 million and is part of the health care sector and drugs industry. Shares are up 11.97% year-to-date as of the close of trading on Thursday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats. The stock currently has a dividend yield of 4.2%. The company has a P/E ratio of 19.1. Currently, there are no analysts who rate PetMed Express a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hyperion Therapeutics (HPTX) - FREE Research Report

Nash Christine A, who is SVP & Chief Commercial Officer at Hyperion Therapeutics, sold 5,000 shares at $24.82 on Jan. 22, 2015. Following this transaction, the SVP & Chief Commercial Officer owned 28,903 shares meaning that the stake was reduced by 14.75% with the 5,000-share transaction.

The shares most recently traded at $24.70, down $0.12, or 0.47% since the insider transaction. Historical insider transactions for Hyperion Therapeutics go as follows:

  • 4-Week # shares sold: 148
  • 12-Week # shares sold: 148
  • 24-Week # shares sold: 148

The average volume for Hyperion Therapeutics has been 191,200 shares per day over the past 30 days. Hyperion Therapeutics has a market cap of $502.5 million and is part of the health care sector and drugs industry. Shares are up 3.92% year-to-date as of the close of trading on Thursday.

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. Currently, there are 5 analysts who rate Hyperion Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HPTX - FREE

TheStreet Quant Ratings rates Hyperion Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Hyperion Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ocean Power Technologies (OPTT) - FREE Research Report

Heinz David R, who is Chief Operating Officer at Ocean Power Technologies, bought 20,000 shares at $0.52 on Jan. 22, 2015. Following this transaction, the Chief Operating Officer owned 147,033 shares meaning that the stake was boosted by 15.74% with the 20,000-share transaction.

The shares most recently traded at $0.50, down $0.02, or 3.4% since the insider transaction. Historical insider transactions for Ocean Power Technologies go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 5,000

The average volume for Ocean Power Technologies has been 192,700 shares per day over the past 30 days. Ocean Power Technologies has a market cap of $9.1 million and is part of the industrial goods sector and industrial industry. Shares are down 24.34% year-to-date as of the close of trading on Thursday.

Ocean Power Technologies, Inc. develops and commercializes proprietary systems that generate electricity by harnessing the renewable energy of ocean waves primarily in the United States, Europe, Asia, and Australia. Currently, there are no analysts who rate Ocean Power Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPTT - FREE

TheStreet Quant Ratings rates Ocean Power Technologies as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Ocean Power Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null